Enanta Pharmaceuticals, Inc. announced positive topline results from its first-in-pediatrics Phase 2 study evaluating zelicapavir. The study assessed zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV).
An antiviral effect was observed for both the primary and secondary virology endpoints in the study. The trial enrolled a total of 96 participants, with 70 receiving zelicapavir and 26 receiving placebo.
These results demonstrate zelicapavir's potential as a treatment for RSV in young children, a population with significant unmet medical needs. The positive data supports the continued development of this key pipeline candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.